- Home
- VEL vs TBPH Comparison
VEL vs TBPH Comparison
Compare VEL & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VEL | TBPH |
|---|---|---|
| Founded | 2004 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 765.5M | 824.9M |
| IPO Year | 2019 | 2013 |
Fundamental Metrics
Financial Performance| Metric | VEL | TBPH |
|---|---|---|
| Price | $17.02 | $16.16 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $22.00 | $18.40 |
| AVG Volume (30 Days) | 54.5K | ★ 297.6K |
| Earning Date | 05-06-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 43.98 | ★ 279.13 |
| EPS | ★ 0.57 | N/A |
| Revenue | N/A | ★ $15,386,000.00 |
| Revenue This Year | $6.01 | $8.46 |
| Revenue Next Year | $19.02 | N/A |
| P/E Ratio | $30.14 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $16.19 | $9.10 |
| 52 Week High | $21.40 | $21.03 |
Technical Indicators
Market Signals| Indicator | VEL | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 35.87 | 43.09 |
| Support Level | N/A | $16.14 |
| Resistance Level | $19.25 | $17.21 |
| Average True Range (ATR) | 0.63 | 0.38 |
| MACD | -0.22 | -0.10 |
| Stochastic Oscillator | 17.10 | 16.81 |
Price Performance
Historical ComparisonAbout VEL Velocity Financial Inc.
Velocity Financial Inc is a United States-based real estate finance company. Company operates in a large fragmented market with substantial demand for financing and limited supply of institutional financing alternative The company originates and manages investor loans secured by residential rental and small commercial properties. The company earns revenue in the form of interest income. It operates in New York, California, Florida, New Jersey, and other states.
About TBPH Theravance Biopharma Inc.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.